New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
W S
WS
Colucci
R F
RF
Wright
E
E
Braunwald
D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; D000284:Administration, Oral; D000631:Aminopyridines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000676:Amrinone; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003067:Coenzymes; D017335:Enoximone; D006321:Heart / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use; D007275:Injections, Intravenous; D020105:Milrinone; D009543:Nifedipine / Q000031:analogs & derivatives / Q000627:therapeutic use; D010099:Oxyfedrine / Q000031:analogs & derivatives / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011724:Pyridazines / Q000627:therapeutic use; D011728:Pyridones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000627:therapeutic use
D000631:Aminopyridines; D002316:Cardiotonic Agents; D003067:Coenzymes; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D011724:Pyridazines; D011728:Pyridones; D011799:Quinazolines; D014451:Ubiquinone; C039686:piroximone; C041648:pimobendan; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; D017335:Enoximone; C040850:quazinone; D010099:Oxyfedrine; C024989:coenzyme Q10; C029758:sulmazole; D009543:Nifedipine; D020105:Milrinone; D000676:Amrinone; C039523:alifedrine